cheap copies of its drugs, particularly anti depressants paxil and wellbutrin, and a weak dollar had hit profits, but global sales were up 1% in 2004. the firm is confident its new drug pipeline will deliver profits despite the failure of an obesity drug. glaxo is relying on new treatments for conditions such as cancer, diabetes, depression, hiv aids and allergies to lift the pace of sales growth after several disappointing years.